International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 1 , Pages 36-42 , January 2010

Equivalent Biochemical Control and Improved Prostate-Specific Antigen Nadir After Permanent Prostate Seed Implant Brachytherapy Versus High-Dose Three-Dimensional Conformal Radiotherapy and High-Dose Conformal Proton Beam Radiotherapy Boost

Portions of this study presented at American Society for Clinical Oncology 2005 Annual Meeting as a general poster presentation and American Society for Therapeutic Radiology and Oncology 2005 Annual Meeting as an oral presentation.

  • Siavash Jabbari, M.D.

      Affiliations

    • Department of Radiation Oncology, University of California San Francisco, School of Medicine, San Francisco, CA
    • ,
  • Vivian K. Weinberg, Ph.D.

      Affiliations

    • Department of Urology, University of California San Francisco, School of Medicine, San Francisco, CA
    • ,
  • Katsuto Shinohara, M.D.

      Affiliations

    • Department of Biostatistics Core, University of California San Francisco, School of Medicine, San Francisco, CA
    • ,
  • Joycelyn L. Speight, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, University of California San Francisco, School of Medicine, San Francisco, CA
    • Department of Biostatistics Core, University of California San Francisco, School of Medicine, San Francisco, CA
    • ,
  • Alexander R. Gottschalk, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, University of California San Francisco, School of Medicine, San Francisco, CA
    • ,
  • I.-Chow Hsu, M.D.

      Affiliations

    • Department of Radiation Oncology, University of California San Francisco, School of Medicine, San Francisco, CA
    • ,
  • Barby Pickett, M.S.

      Affiliations

    • Department of Radiation Oncology, University of California San Francisco, School of Medicine, San Francisco, CA
    • ,
  • Patrick W. McLaughlin, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI
    • ,
  • Howard M. Sandler, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI
    • ,
  • Mack Roach III, M.D.

      Affiliations

    • Department of Radiation Oncology, University of California San Francisco, School of Medicine, San Francisco, CA
    • Department of Urology, University of California San Francisco, School of Medicine, San Francisco, CA
    • Corresponding Author InformationReprint requests to: Mack Roach III, M.D., Department of Radiation Oncology, University of California, San Francisco, School of Medicine, 1600 Divisadero Ave., Suite H1031, San Francisco CA 94115. Tel: (415) 353-7175; Fax: (415) 353-9883

Received 17 November 2008 ,Revised 10 January 2009 ,Accepted 14 January 2009.

References 

  1. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:25–33
  2. Potters L, Klein EA, Kattan MW, et al. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol. 2004;71:29–33
  3. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  4. Beyer DC, Brachman DG. Failure free survival following brachytherapy alone for prostate cancer: Comparison with external beam radiotherapy. Radiother Oncol. 2000;57:263–267
  5. Pickett B, Kurhanewicz J, Pouliot J, et al. Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level. Int J Radiat Oncol Biol Phys. 2006;65:65–72
  6. Trofimov A, Nguyen PL, Coen JJ, et al. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: A treatment planning comparison. Int J Radiat Oncol Biol Phys. 2007;69:444–453
  7. Zietman AL. The Titanic and the iceberg: Prostate proton therapy and health care economics. J Clin Oncol. 2007;25:3565–3566
  8. Goitein M. Magical protons?. Int J Radiat Oncol Biol Phys. 2008;70:654–656
  9. Goitein M, Cox JD. Should randomized clinical trials be required for proton radiotherapy?. J Clin Oncol. 2008;26:175–176
  10. Konski A, Speier W, Hanlon A, et al. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?. J Clin Oncol. 2007;25:3603–3608
  11. Pollack A. Hospitals look to nuclear tool to fight cancer. New York: The New York Times; 2007;
  12. Zietman AL. Correction: Inaccurate analysis and results in a study of radiation therapy in adenocarcinoma of the prostate. JAMA. 2008;299:898–899
  13. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA. 2005;294:1233–1239
  14. Grimm PD, Blasko JC, Sylvester JE, et al. 10-Year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys. 2001;51:31–40
  15. Alcantara P, Hanlon A, Buyyounouski MK, et al. Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. Cancer. 2007;109:41–47
  16. Zelefsky MJ, Kuban DA, Levy LB, et al. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys. 2007;67:327–333
  17. Ray ME, Thames HD, Levy LB, et al. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysis. Int J Radiat Oncol Biol Phys. 2006;64:1140–1150
  18. Sahgal A, Roach M. Permanent prostate seed brachytherapy: A current perspective on the evolution of the technique and its application. Nat Clin Pract Urol. 2007;4:658–670
  19. American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: Guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
  20. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  21. Sylvester JE, Grimm PD, Blasko JC, et al. 15-Year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy: Seattle experience. Int J Radiat Oncol Biol Phys. 2007;67:57–64
  22. Potters L, Morgenstern C, Calugaru E, et al. 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol. 2008;179(5 Suppl):S20–S24
  23. Stone NN, Stock RG, Unger P. Intermediate term biochemical-free progression and local control following 125iodine brachytherapy for prostate cancer. J Urol. 2005;173:803–807
  24. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67–74
  25. Cahlon O, Zelefsky MJ, Shippy A, et al. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys. 2008;71:330–337
  26. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24:1990–1996
  27. Zelefsky MJ, Yamada Y, Fuks Z, et al. Long-term results of conformal radiotherapy for prostate cancer: Impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys. 2008;71:1028–1033
  28. Moyers MF, Pouliot J, Orton CG. Point/counterpoint: Proton therapy is the best radiation treatment modality for prostate cancer. Med Phys. 2007;34:375–378
  29. Slater JD, Rossi CJ, Yonemoto LT, et al. Proton therapy for prostate cancer: The initial Loma Linda University experience. Int J Radiat Oncol Biol Phys. 2004;59:348–352
  30. Mock U, Bogner J, Georg D, et al. Comparative treatment planning on localized prostate carcinoma conformal photon- versus proton-based radiotherapy. Strahlenther Onkol. 2005;181:448–455
  31. Schulz-Ertner D, Tsujii H. Particle radiation therapy using proton and heavier ion beams. J Clin Oncol. 2007;25:953–964
  32. Feigenberg SJ, Lee WR, Desilvio ML, et al. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. Int J Radiat Oncol Biol Phys. 2005;62:956–964
  33. Lee WR, Bae K, Lawton C, et al. Late toxicity and biochemical recurrence after external-beam radiotherapy combined with permanent-source prostate brachytherapy: Analysis of Radiation Therapy Oncology Group study 0019. Cancer. 2007;109:1506–1512
  34. Robinson JW, Moritz S, Fung T. Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma. Int J Radiat Oncol Biol Phys. 2002;54:1063–1068
  35. Eade TN, Horwitz EM, Ruth K, et al. A comparison of acute and chronic toxicity for men with low-risk prostate cancer treated with intensity-modulated radiation therapy or (125)I permanent implant. Int J Radiat Oncol Biol Phys. 2008;71:338–345
  36. Vargas C, Wagner M, Indelicato D, et al. Image guidance based on prostate position for prostate cancer proton therapy. Int J Radiat Oncol Biol Phys. 2008;71:1322–1328
  37. de Crevoisier R, Tucker SL, Dong L, et al. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:965–973
  38. Vargas C, Wagner M, Mahajan C, et al. Proton therapy coverage for prostate cancer treatment. Int J Radiat Oncol Biol Phys. 2008;70:1492–1501
  39. Zhang X, Dong L, Lee AK, et al. Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment. Int J Radiat Oncol Biol Phys. 2007;67:620–629
  40. Norderhaug I, Dahl O, Hoisaeter PA, et al. Brachytherapy for prostate cancer: A systematic review of clinical and cost effectiveness. Eur Urol. 2003;44:40–46
  41. Gottschalk AR, Roach M. The use of hormonal therapy with radiotherapy for prostate cancer: Analysis of prospective randomised trials. Br J Cancer. 2004;90:950–954
  42. Roach M, Lu J, Pilepich MV, et al. Predicting long-term survival, and the need for hormonal therapy: A meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys. 2000;47:617–627

 Conflict of interest: K. Shinohara is a consultant for Nihon Mediphysics, Co., Ltd.

PII: S0360-3016(09)00125-4

doi: 10.1016/j.ijrobp.2009.01.029

International Journal of Radiation Oncology * Biology * Physics
Volume 76, Issue 1 , Pages 36-42 , January 2010

Article Tools

* Image Usage & Resolution